Europe's CAR-T payment terms, read from the hospital's side
Five European markets and one U.S. model link payment for advanced therapies to outcomes. Read from the treatment center's side, the arrangements differ in who pays whom, when, and on what evidence, and none of them settles the center's own payment terms by itself.
Two examples, from the treatment center's side.
Italy's published 2019 Kymriah arrangement
AIFA determination of 2019: the treating center pays the manufacturer in stages
The center's exposure. Part 1 is owed at infusion whatever the outcome, and the registry duty runs on every patient. The center's own funding from the region sits outside these terms.
The U.S. Medicaid CGT Access Model
Gene therapy for sickle cell disease, under CMS's model terms
The center's exposure. The rebate runs from the manufacturer to the state, not to the center. The center's payment depends on the state's terms and on meeting the registry condition; its timing is not set by the model.
- Money that moves whatever the outcome
- Money that depends on the outcome
- The record that decides an outcome or a payment
- The treatment center
An outcome-linked rebate does not, by itself, establish the treatment center's payment terms.
Under Italy's published 2019 Kymriah terms, the treating center pays the manufacturer in parts, with the later parts owed only if the outcome holds. Under the U.S. CGT Access Model for sickle cell disease, the manufacturer's rebate runs to the participating state Medicaid program, and the state pays the treating center directly for the drug on its own terms. These are different payment relationships. In each, the treatment center still has to establish its own payment timing, purchasing obligations, evidence requirements and financial exposure.
The question
Outcome-based payment for advanced therapies is often described from the payer's chair: a rebate if the therapy fails, a staged price if it works. For a hospital or cancer center, the useful question is narrower. Under each arrangement, when does cash reach the treatment center, how much of it is conditional, who supplies the evidence that decides the condition, and who is left holding the drug cost if the answer is late or missing?
This analysis takes the five largest European markets' CAR-T arrangements as reported at the end of 2019, one current German gene-therapy agreement, and the live U.S. Cell and Gene Therapy Access Model, and reads each one from the treatment center's side. It is a reading of public documents. HealthPulse is not the first to study these arrangements; IQVIA and Milliman, among others, have published on them. The contribution here is the treatment-center view.
The mechanisms, side by side
| Country and therapy | Arrangement | Who pays whom | When | What triggers an adjustment | Who supplies the evidence | Who carries the risk |
|---|---|---|---|---|---|---|
| Italy (Kymriah, 2019 AIFA determination) | Payment at results in three parts, with a confidential discount off the list price. | The treating center, which the regions designate, pays the manufacturer. | At infusion, at six months and at twelve months. | The agreed outcome is reached and still holds at each date. | The center completes AIFA's web registry: an enrollment form showing the patient was eligible, then follow-up forms. | The manufacturer, for parts 2 and 3: it is paid them only if the outcome holds. The center owes part 1 at infusion whatever the outcome, and carries the registry duty; its own reimbursement from the region sits outside the determination. |
| Italy (Yescarta, 2019, as reported) | Three parts, all after infusion. | Treating center to manufacturer. | Reportedly at 180, 270 and 365 days. | The patient reaches each date with the agreed outcome. | AIFA registry. | The manufacturer carries more than under the Kymriah terms, since nothing is paid before day 180. |
| Spain (Kymriah and Yescarta, 2019, as reported) | Two outcome-linked payments through the Valtermed registry. | The national health service to the manufacturer. | Kymriah: reportedly 52% at treatment and 48% at eighteen months. Yescarta: reportedly about 118,000 euros then 209,000 euros, timing linked to survival. | Kymriah: a complete response, achieved and sustained. Yescarta: survival. | Valtermed, the Spanish health service's web registry, launched November 2019. | The manufacturer, for the second payment. |
| Germany (CAR-T, 2019, as reported) | Outcome-based rebates agreed with insurer groups covering more than 41 million people. | The manufacturer rebates the statutory insurer. | After a patient dies within a period the agreements do not disclose. | Death within the period. | Insurer claims and the agreement's own reporting. | The manufacturer, for the rebate. The hospital is paid separately through a NUB add-on it negotiates with insurers, which covers the product and not apheresis, administration or toxicity management. |
| Germany (Roctavian for hemophilia A, 2023 agreement) | A collective pay-for-performance model with a minimum three-year term. | Manufacturer and the GKV-Spitzenverband, for all statutory insurers. | The reimbursement amount is adjusted on a fixed schedule. | Treatment success or failure, as documented in the German Hemophilia Registry. | The national registry, not the manufacturer's data. | Shared across the insured cohort rather than settled patient by patient. |
| France (2019) | Coverage with evidence development: reimbursed access first, reassessed yearly. | The health insurance system pays. Hospitals get supplementary funding for listed costly medicines outside the standard DRG tariff. | Access began before marketing authorization under the ATU scheme; the price is reassessed annually on registry and trial data. | No per-patient trigger. The price and the health-benefit rating move with the evidence. | A CAR-T registry recording survival, remission, progression and adverse events at 28 days, 100 days, 6 months and beyond. | The manufacturer carries price risk at reassessment; the hospital's funding depends on the medicine staying on the supplementary list. |
| England (2019 to now) | Managed access through the Cancer Drugs Fund, with a confidential discount and a time-limited agreement to collect data for a later price review. | NHS England pays, from a dedicated fund that NICE states has an annual budget of 340 million pounds (the Innovative Medicines Fund has the same). | During the managed-access period; routine commissioning is decided afterward. | No per-patient trigger. The question at review is whether the medicine is cost effective for routine use. | Trial follow-up and data from NHS patients, under the managed-access agreement. | The manufacturer, at the review. The treating hospital is funded for the case. |
| United States (CMS Cell and Gene Therapy Access Model, active) | CMS negotiates key terms, including price discounts and outcome-based rebates, that become contracts between manufacturers and participating state Medicaid programs. The first condition is sickle cell disease. | The manufacturer pays supplemental rebates to the state. The state, or its managed-care plan, pays the treating provider by direct reimbursement for the drug, separately from the inpatient payment. | The model runs an administration period, a measurement period and a reconciliation period; evaluation reports start in 2027 and the model ends in 2035. | If the therapy improves health outcomes less than expected, the manufacturer repays the payer part of what was paid. | The CMS-designated registry and its study. States make the payment for administering the drug conditional on the provider's participation; CMS supports data collection and reconciliation. | The manufacturer, for the rebate. The treatment center is not a model participant; it is paid by the state under a required contract, and 340B does not apply because the therapy is given inpatient. |
Italy: AIFA Determina n. 1264/2019 for Kymriah (payment at results at infusion, six and twelve months; registry enrollment and follow-up by the designated centers; 18-month contract). Yescarta timing, Spain's percentages and amounts, and the German CAR-T rebate terms are as reported in Jorgensen, Hanna and Kefalas (2020), who cite press and secondary sources; the contracts themselves are confidential. Germany 2023: GKV-Spitzenverband release of December 8, 2023. England: NICE, managed access (read October 13, 2026). United States: CMS, CGT Access Model page (last modified September 30, 2026) and its FAQ (last modified September 22, 2026).
When the outcome-linked payments fall due
| Arrangement | Payments |
|---|---|
| Italy, Kymriah | part 1 at infusion; part 2 at 6 months; part 3 at 12 months |
| Italy, Yescarta (reported) | part 1 at 6 months; part 2 at 9 months; part 3 at 12 months |
| Spain, Kymriah (reported) | 52% at infusion; 48% at 18 months |
| Germany, CAR-T (reported) | rebate if the patient dies within an undisclosed period |
| England, CDF | hospital funded; price reviewed at the end of managed access |
| U.S., CGT Access Model | center paid directly under state terms; manufacturer rebate to the state after reconciliation |
Timeline data
| Arrangement | Payments |
|---|---|
| Italy, Kymriah | part 1 at infusion; part 2 at 6 months; part 3 at 12 months |
| Italy, Yescarta (reported) | part 1 at 6 months; part 2 at 9 months; part 3 at 12 months |
| Spain, Kymriah (reported) | 52% at infusion; 48% at 18 months |
| Germany, CAR-T (reported) | rebate if the patient dies within an undisclosed period |
| England, CDF | hospital funded; price reviewed at the end of managed access |
| U.S., CGT Access Model | center paid directly under state terms; manufacturer rebate to the state after reconciliation |
Germany and England, read on their own terms
Neither belongs in the same diagram as the Italian terms, and they differ from each other.
Germany
The 2019 CAR-T agreements, as reported, are patient-level rebates: the manufacturer repays the statutory insurer when a patient dies within a period the agreements do not disclose. The hospital is paid separately, through an NUB add-on it negotiates with insurers, which covers the product and not apheresis, administration or toxicity management. The 2023 Roctavian agreement is a different design again: a collective pay-for-performance model with the GKV-Spitzenverband, adjusted on a fixed schedule against the national hemophilia registry.
England
England uses managed access rather than a rebate. NHS England pays from a dedicated fund while data are collected under a time-limited agreement, and NICE then reviews whether the medicine is cost effective for routine use. The treating hospital is funded for the case; the price question is settled at the review, between the manufacturer and the NHS.
What a U.S. program should take from this
Separate the payer's arrangement from your own payment terms. A payer can hold a large rebate while the hospital funds acquisition and delivery for months. In Germany's 2019 rebates and in the CMS model, the outcome-linked money runs between manufacturer and payer, and the center's payment is set elsewhere: through a negotiated add-on in Germany, and through the state's direct payment, conditional on registry participation, in the U.S. model. Under Italy's terms the center is itself a party: it pays part 1 at infusion whatever happens, reportedly nothing before day 180 under the Yescarta terms, on a product listed around 300,000 to 330,000 euros in 2019, and its registry work decides the later parts.
Past that principle the answers are specific to a program, and they are the work HealthPulse does with one. The questions it works through:
- Is the center a party to the outcome-linked terms at all, and what does it owe before the outcome is known?
- When is the center actually paid, under whose terms, and what has to be filed before it is?
- Which record decides the outcome, who keeps it, and is it named in the contract before the first infusion?
- What happens to the money when a patient is lost to follow-up or a registry entry is late? None of the public sources here say.
- Where does the drug arrangement end and the center's payment for apheresis, administration and toxicity management begin?
Each answer turns on the center's working capital, payer mix and registry capacity, which is why the analysis is built with the program and not read off this page.
What this analysis does not show
- Current European terms. The CAR-T arrangements are as reported for late 2019 and several have been renegotiated since; the Roctavian agreement is the only post-2020 European term here.
- The contracts. Amounts, percentages and periods marked as reported come from a peer-reviewed review that cites press and secondary sources.
- How U.S. commercial payers or Medicare would behave. The CMS model is Medicaid, and its first condition is sickle cell disease, not CAR-T.
- That any of these designs is right for a given program. The treatment center's working capital, payer mix and registry capacity decide that.
Sources
Agenzia Italiana del Farmaco, Determina n. 1264/2019 (Kymriah), Gazzetta Ufficiale n. 188, August 12, 2019. GKV-Spitzenverband, press release, December 8, 2023 (Roctavian). National Institute for Health and Care Excellence, Managed access, read October 13, 2026. Centers for Medicare & Medicaid Services, Cell and Gene Therapy Access Model (page last modified September 30, 2026) and CGT Access Model frequently asked questions (page last modified September 22, 2026). Jorgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020;8(1):1715536. Reading and treatment-center analysis by HealthPulse Advisors.
Offered outcome-linked terms?
The first piece of work is to establish what they settle for your center and what they leave open: payment timing, purchasing obligations, evidence duties and exposure.
Discuss a decision